Adenovirus-specific IgG maturation as a surrogate marker in acute exacerbations of COPD

Chest

Volumn 146, Issue 2, 2014, Pages 339-347

  Boeck, Lucas ^a   Gencay, Mikael ^a   Roth, Michael ^a   Hirsch, Hans H ^b   Christ Crain, Mirjam ^b   Mueller, Beat ^c   Tamm, Michael ^a   Stolz, Daiana ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c CANTONAL HOSPITAL AARAU   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ADENOVIRUS INFECTION; ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DEATH; DISEASE EXACERBATION; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; HUMORAL IMMUNITY; IMMUNOGLOBULIN MATURATION; IMMUNOGLOBULIN STRUCTURE, FUNCTION AND VARIABILITY; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENCE RISK; SERODIAGNOSIS;

ADENOVIRIDAE; ADENOVIRIDAE INFECTIONS; AGED; ANTIVIRAL AGENTS; B-CELL MATURATION ANTIGEN; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PATIENT READMISSION; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL RATE; SWITZERLAND;

EID: 84905647297     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.13-2307     Document Type: Article

References (34)

1. Hurst JR, Perera WR, Wilkinson TMA, Donaldson GC, Wedzicha JA. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;173(1):71-78. (Pubitemid 43069790)
2. Rutgers SR, Postma DS, ten Hacken NH, et al. Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax. 2000;55(1):12-18. (Pubitemid 30248773)
3. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(26):2645-2653. (Pubitemid 38787999)
4. Shaykhiev R, Krause A, Salit J, et al. Smoking-dependent reprogramming of alveolar macrophage polarization: implication for pathogenesis of chronic obstructive pulmonary disease. J Immunol. 2009;183(4):2867-2883.
5. Majo J, Ghezzo H, Cosio MG. Lymphocyte population and apoptosis in the lungs of smokers and their relation to emphysema. Eur Respir J. 2001;17(5):946-953. (Pubitemid 32600344)
6. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol. 2008;8(3):183-192. (Pubitemid 351323287)
7. Gosman MME, Willemse BWM, Jansen DF, et al; Groningen and Leiden Universities Corticosteroids in Obstructive Lung Disease Study Group. Increased number of B-cells in bronchial biopsies in COPD. Eur Respir J. 2006;27(1):60-64. (Pubitemid 43092667)
8. van der Strate BWA, Postma DS, Brandsma C-A, et al. Cigarette smoke-induced emphysema: a role for the B cell? Am J Respir Crit Care Med. 2006;173(7):751-758.
9. Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. Lancet. 2011;378(9795):1015-1026.
10. Lee S-H, Goswami S, Grudo A, et al. Antielastin autoimmunity in tobacco smoking-induced emphysema. Nat Med. 2007;13(5):567-569. (Pubitemid 46828488)
11. Ferson M, Edwards A, Lind A, Milton GW, Hersey P. Low natural killer-cell activity and immunoglobulin levels associated with smoking in human subjects. Int J Cancer. 1979;23(5):603-609. (Pubitemid 9168661)
12. Cosio MG, Saetta M, Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med. 2009;360(23):2445-2454.
13. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest. 2000;117(5)(suppl-2):398S-401S.
14. Cazzola M, MacNee W, Martinez FJ, et al; American Thoracic Society; European Respiratory Society Task Force on outcomes of COPD. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008;31(2):416-469.
15. Stolz D, Christ-Crain M, Bingisser R, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest. 2007;131(1):9-19. (Pubitemid 46122969)
16. Levett PN, Sonnenberg K, Sidaway F, et al. Use of immunoglobulin G avidity assays for differentiation of primary from previous infections with West Nile virus. J Clin Microbiol. 2005;43(12):5873-5875. (Pubitemid 43100631)
17. Meurman O, Waris M, Hedman K. Immunoglobulin G antibody avidity in patients with respiratory syncytial virus infection. J Clin Microbiol. 1992;30(6):1479-1484.
18. Hedman K, Lappalainen M, Seppäiä I, Mäkelä O. Recent primary toxoplasma infection indicated by a low avidity of specific IgG. J Infect Dis. 1989;159(4):736-740. (Pubitemid 19105628)
19. Lefevre-Pettazzoni M, Le Cam S, Wallon M, Peyron F. Delayed maturation of immunoglobulin G avidity: implication for the diagnosis of toxoplasmosis in pregnant women. Eur J Clin Microbiol Infect Dis. 2006;25(11):687-693. (Pubitemid 44806776)
20. Hedman K, Vaheri A, Brummer-Korvenkontio M. Rapid diagnosis of hantavirus disease with an IgG-avidity assay. Lancet. 1991;338(8779):1353-1356.
21. Romero-Steiner S, Musher DM, Cetron MS, et al. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin Infect Dis. 1999;29(2):281-288. (Pubitemid 29380185)
22. Fujinami RS, von Herrath MG, Christen U, Whitton JL. Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. Clin Microbiol Rev. 2006;19(1):80-94. (Pubitemid 43157648)
23. Orange JS, Ballow M, Stiehm ER, et al. Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2012;130(suppl 3):S1-S24.
24. Connors AF Jr, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med. 1996;154(4 pt 1):959-967.
25. Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847-852. (Pubitemid 35178607)
26. Hayashi S. Latent adenovirus infection in COPD. Chest. 2002;121(5-suppl):183S-187S.
27. Matsuse T, Hayashi S, Kuwano K, Keunecke H, Jefferies WA, Hogg JC. Latent adenoviral infection in the pathogenesis of chronic airways obstruction. Am Rev Respir Dis. 1992;146(1):177-184.
28. Retamales I, Elliott WM, Meshi B, et al. Amplification of inflammation in emphysema and its association with latent adenoviral infection. Am J Respir Crit Care Med. 2001;164(3):469-473. (Pubitemid 32778218)
29. Ogawa E, Elliott WM, Hughes F, Eichholtz TJ, Hogg JC, Hayashi S. Latent adenoviral infection induces production of growth factors relevant to airway remodeling in COPD. Am J Physiol Lung Cell Mol Physiol. 2004;286(1):L189-L197. (Pubitemid 38055875)
30. Macek V, Sorli J, Kopriva S, Marin J. Persistent adenoviral infection and chronic airway obstruction in children. Am J Respir Crit Care Med. 1994;150(1):7-10. (Pubitemid 24209928)
31. McManus TE, Marley A-M, Baxter N, et al. Acute and latent adenovirus in COPD. Respir Med. 2007;101(10):2084-2090. (Pubitemid 47324251)
32. Delgado MF, Coviello S, Monsalvo AC, et al. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med. 2009;15(1):34-41.
33. de Torres JP, Marín JM, Casanova C, et al. Lung cancer in patients with chronic obstructive pulmonary disease - incidence and predicting factors. Am J Respir Crit Care Med. 2011;184(8):913-919.
34. Hurst JR, Vestbo J, Anzueto A, et al; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128-1138.